In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Lessons From A Life Sciences Lifetime: An Interview With Sir John Bell

Professor Sir John Bell talks to In Vivo about how the life sciences sector has evolved during his career, lessons he has learned along the way, and the biggest challenges and changes ahead for the industry in 2019.

Leadership Outlook 2019 BioPharmaceutical

Cross-Country Collaborations, Business As Usual?

Pharmaceutical companies cannot afford to ignore the growing number of cross-country collaborations springing up in Europe aimed at securing more affordable medicines through actions such as jointly negotiated pricing deals. In Vivo looks at the factors that may influence the rise or fall of these collaborations and at how they may eventually make companies rethink the way they do business.

Market Access Outlook 2019 Pricing Strategies

Brexit And Cooperation: Insights From Danish Medicines Agency Head Thomas Senderovitz

It was inevitable that Brexit would be the key theme of an interview with Danish Medicines Agency head Thomas Senderovitz earlier this year. The senior European regulator oversees one of the agencies that has taken on new staff to help deal with the impact, in drug regulatory terms, of the vote by the UK in June 2016 to leave the European Union. Senderovitz also chairs the management group of the EU Heads of Medicines Agencies network.

Leadership Policy & Regulation Outlook 2019

Cell And Gene Therapy Logistics Requires Early Planning

It has become standard practice for manufacturing to get early attention in the cell and gene therapy development, but logistics is often not considered until closer to commercialization, which could be a strategic mistake given the speed with which new treatments are being approved.

Manufacturing Outlook 2019 Market Intelligence
Advertisement

Datamonitor Healthcare Podcasts


Recent Tweets from In Vivo


Stem Cell Progress Research in the US: Where are we now?

The history of stem cell research has been marked by a combination of great promise, disappointment and controversy. But progress is being made, with a number of stem cell therapies approved and many more in the late-stage pipeline. While the US has lagged behind other regions in stem cell therapy approvals, recent developments on the regulatory front are intended to provide a clearer path forward and accelerate development.

Read More

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop Now

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Medical Aesthetics: A Untapped Pharma Market With Incoming Competition

Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.

Business Strategies Growth

Israel's Medtech Market Evolution: Seeking The Next Big Thing

Medtronic’s multi-billion-dollar acquisition of Mazor Robotics in 2018 marked a record-breaking milestone for Israel’s life sciences industry as the largest amount ever paid for an Israeli company in the medical sector, beating Mitsubishi Tanabe Pharma’s $1.1 billion acquisition of Neuroderm in 2017. In Vivo investigates how aMoon II, a new VC fund, aims to produce the industry’s next big giant.

Growth Deals

Boston Scientific's Drive To Add To Core Strength Continues With BTG Buy

When Boston Scientific chief medical officer Ian Meredith spoke in mid-2018 of the group's appetite for core M&A, there was a sense that more strategic moves were likely before the year was out. The inference was right, and a busy year for Boston Scientific got much busier when it made a cash offer for UK interventional medicine specialist BTG PLC. The bid values the target company at £4.28 billion, and completion is expected by mid-2019.

M & A Cancer

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Pharma Wakes Up To Transformative Progress In Hearing Loss Research

The cacophony of noise in the modern world is one factor driving the loss of hearing throughout humankind, a condition that until now has not been thought amenable to pharmacological intervention. But with small-molecule approaches to regenerating cells in the inner ear bearing fruit, biotech and pharmaceutical companies are taking renewed interest in the sector. 

Innovation Research and Development Strategies

Data, Data, Everywhere, But How Much Of It Makes A Real Difference?

Having a single patient's complete health care information all in one place was a dream that US visionaries began to talk up around a decade ago. The idea was that fast, electronic support for doctors would aid clinical decision making and efficiency. Ten years on, there is still much work to do before the dream is realized, says Philips' Carla Kriwet. But a solution is within reach.

Digital Health Medical Device

Gene Therapy’s Next Big Challenge: Manufacturing

As the pipeline and market for novel cell and gene therapies expands, it is time for drug developers to address other critical aspects in the logistical chain – and for these complex therapies a lot of those issues relate to manufacturing. Looking at specific cases, In Vivo has underlined the main manufacturing challenges facing cell and gene therapy developers, and highlighted methods and approaches being used to generate solutions. 

Regenerative Medicine Outlook 2019

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Where Angels Fear To Tread: Lessening The Perils Of CRISPR-Based Therapies

CRISPR is in the headlines once again, but for all the wrong reasons. While germline gene editing remains taboo in legitimate research, it is a reminder that there is much to be learned in ensuring the safety of the technique in general. AstraZeneca has developed a new method which it believes will help avoid off-target effects, an executive explains to In Vivo.

Outlook 2019 Leadership

What’s Under The Iceberg: GE Healthcare’s Deep Dive Look At Future Of Gene Therapy

Cell and gene therapy represent a transformative advance in drug delivery and outcomes, with implications equally as important to human progress as the digital revolution that began three decades ago.In Vivo speaks with a key player in this evolving field, GE Healthcare’s strategy manager for cell and gene therapy and board member of the Alliance for Regenerative Medicine, Phil Vanek, PhD.

C-Suite Speaks Leadership

Execs On The Move, Nov 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership Appointments

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Pilots Between NHS And Pharma Finally Take Off

The majority of pharmaceutical companies in the UK work closely with the NHS and In Vivo spoke to one of them – Janssen – to see how successful industry, health care providers and payers have been in breaking out of their silos and collaborating.

United Kingdom Market Access

Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer

The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.

Biosimilars Market Access

Can Modicare Reshape India’s Health Care Paradigm?

India’s new government-funded health care program expects to expand access to treatment to more than 100 million families. Can it effectively deliver on its promise and also materially expand opportunities for hospitals and pharma?

Market Access Outlook 2019

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

The Harsh Light Of Hard Facts: Valuing Pharma In A Made For Measure World

With a challenging new decade of scientific discovery looming, 2019 is the positioning year for biopharma to make value, transparency, information and culture work seamlessly to achieve innovations that matter to patients, payers and society.

Outlook 2019 Market Intelligence

Will Recent Excessive Pricing Cases Lay Down Precedent For Future?

The recent upsurge in cases of high drug prices being pursued by competition authorities in Europe could help to lay down some markers for judging what is an “excessive” price in future. At the same time, Brexit could see the UK and the EU begin to drift apart in terms of how they apply competition law to pricing issues.

Market Intelligence Policy & Regulation

Future Of Cardio And Mental Health Will Be Defined By Digital Advances

Cardiovascular diseases are responsible for 30% of worldwide deaths, and about 25% of the global population experiences mental illness each year. The negative impact of these conditions on society remain substantial. Development of digital tools to provide support to high-risk groups and patients, healthcare providers, and communities in general, is an area of significant opportunity.

Digital Health Market Intelligence
UsernamePublicRestriction

Register

Advertisement